Home > Press > Harris & Harris Group Invests in Ancora Pharmaceuticals
Harris & Harris Group, Inc., announced today that it has invested in Ancora Pharmaceuticals Inc., based in Medford, Massachusetts. Douglas W. Jamison, President and COO of Harris & Harris Group, has joined Ancora's Board of Directors.
Harris & Harris Group Invests in Ancora Pharmaceuticals
NEW YORK, NY | Posted on June 4th, 2007
Ancora Pharmaceuticals Inc. is dedicated to enabling synthetic carbohydrate-based product discovery and development utilizing its state-of-the-art carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.
About Harris & Harris Group, Inc.
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 33 initial private equity investments have been in tiny technology-enabled companies. The Company has 21,783,444 shares of common stock outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at http://www.TinyTechVC.com .
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Registration Statement on Form N-2 and Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc., undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website http://www.TinyTechVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
For more information, please click here
Harris & Harris Group, Inc.
Douglas W. Jamison
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015
Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015
UT Dallas engineers twist nanofibers to create structures tougher than bulletproof vests March 27th, 2015
Novel nanoparticle therapy promotes wound healing March 27th, 2015
Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015
Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015